Track topics on Twitter Track topics that are important to you
Cathal Friel, chief executive of Venn Life Sciences Holdings plc (LON:VENN) and founder of Open Orphan, speaks to Proactive London's Andrew Scott after successfully raising £4.5mln in a share placing.
Friel is reversing Open Orphan into Venn in a £5.7mln all-paper deal to bring to the market his platform that helps pharma companies commercialise their products in Europe.
Friel and his team want to grow the company into a full-service consultancy for orphan and rare disease drugs.
Original Article: Venn Life Sciences eyes first acquisition target after £4.5mln raiseNEXT ARTICLE